Diabetes treatments reduce the risk of heart failure in HIV patients

Posted on

Release date: 2015-05-20

A recent study from the University of Washington School of Medicine found that a diabetes treatment drug can reduce inflammation and prevent cardiovascular disease in addition to hypoglycemic effects in HIV patients. This research was published in the international academic journal JCEM.
HIV-infected patients are judged as having death, and their risk of heart failure, diabetes, and other metabolic diseases associated with glucose, insulin, and cholesterol are greatly increased. One of the important drivers is chronic inflammation.
In the study, the researchers found that the antihypertensive drug sitagliptin has a dual role in improving metabolism and reducing inflammation in HIV-positive patients undergoing antiretroviral therapy. Patients taking the drug have decreased blood glucose, and some markers of immune activation and inflammation have also decreased, suggesting that sitagliptin may provide long-term protection to the patient's heart, bone and liver.
The study was the team's second study of sitagliptin in the treatment of HIV patients. In the previous study, the researchers investigated the safety of sitagliptin, and this time they focused their research. The functional study of sitagliptin. During the 8-week study, the researchers divided 36 HIV patients aged 18-65 into two groups, one receiving sitagliptin and the other receiving placebo and their Blood glucose levels, insulin sensitivity, lipid levels, number of immune cells, markers of inflammation, and other health indicators were continuously observed. These patients received antiretroviral therapy during the experiment and their immune status was relatively stable.
In the end, the researchers found that HIV patients taking sitagliptin were effectively controlled for their blood sugar, and inflammation and immune activation markers were reduced, indicating that sitagliptin not only improves symptoms of diabetes, but also immunizes HIV patients. The status is adjusted. Although this finding still requires further long-term clinical validation, it has been proven that sitagliptin is a promising drug.

Source: Bio Valley

Galvanized Steel Pipes

Hot-dip galvanization is a form of galvanization. It is the process of coating iron and steel with zinc, which alloys with the surface of the base metal when immersing the metal in a bath of molten zinc at a temperature of around 840 °F (449 °C). When exposed to the atmosphere, the pure zinc (Zn) reacts with oxygen (O2) to form zinc oxide (ZnO), which further reacts with carbon dioxide (CO2) to form zinc carbonate (ZnCO3), a usually dull grey, fairly strong material that protects the steel underneath from further corrosion in many circumstances. Galvanized steel is widely used in applications where corrosion resistance is needed without the cost of stainless steel, and is considered superior in terms of cost and life-cycle.

Galvanized Steel Pipes,Galvanised Pipe,Galvanised Steel Pipe

JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.spgreenhouse.com